PMID- 37703996
OWN - NLM
STAT- MEDLINE
DCOM- 20231204
LR  - 20231217
IS  - 2666-6367 (Electronic)
IS  - 2666-6367 (Linking)
VI  - 29
IP  - 12
DP  - 2023 Dec
TI  - Consolidative Autotransplantation Achieves High Cure Rates in Adverse-Risk Large 
      B Cell Lymphoma.
PG  - 763.e1-763.e5
LID - S2666-6367(23)01519-1 [pii]
LID - 10.1016/j.jtct.2023.09.005 [doi]
AB  - There remains an unmet need to optimize the first-line treatment of patients with 
      high-risk large B cell lymphoma (LBCL), particularly those with a high 
      International Prognostic Index (IPI) score or a positive interim positron 
      emission tomography (PET) scan who experience poor outcomes with R-CHOP. This 
      study was conducted to evaluate the real-world effectiveness of consolidative 
      autologous stem cell transplantation (ASCT) among patients with high-risk LBCL. 
      This retrospective study included consecutive patients with LBCL and IPI score 4 
      or 5 who underwent consolidative ASCT as part of first-line therapy in Alberta, 
      Canada. Progression-free survival (PFS), overall survival (OS), and 
      disease-specific survival (DSS) were determined using the Kaplan-Meier method. 
      The study cohort comprised 114 patients with median age of 60 years (range, 18 to 
      73 years), of whom 81 (71%) had an IPI score of 4 and 33 (29%) had an IPI score 
      of 5. With a median follow-up of 5.6 years, the 5-year PFS was 72% (95% 
      confidence interval [CI], 62% to 79%), 5-year OS was 74% (95% CI, 64% to 81%), 
      and 5-year DSS was 80% (95% CI, 71% to 87%). There was no significant difference 
      in PFS among patients with and patients without positive interim PET scans 
      (n = 24), MYC and BCL2 and/or BCL6 rearrangements (n = 26), or central nervous 
      system involvement (n = 15). Consolidative ASCT is associated with high cure 
      rates and favorable survival outcomes in patients with high-risk LBCL and may 
      overcome the adverse prognostic impact of a positive interim PET scan.
CI  - Copyright (c) 2023 The American Society for Transplantation and Cellular Therapy. 
      Published by Elsevier Inc. All rights reserved.
FAU - Puckrin, Robert
AU  - Puckrin R
AD  - Tom Baker Cancer Centre and University of Calgary, Calgary, Canada. Electronic 
      address: robert.puckrin@ahs.ca.
FAU - Sterrett, Russell
AU  - Sterrett R
AD  - Cross Cancer Institute and University of Alberta, Edmonton, Canada.
FAU - Chua, Neil
AU  - Chua N
AD  - Cross Cancer Institute and University of Alberta, Edmonton, Canada.
FAU - Owen, Carolyn
AU  - Owen C
AD  - Tom Baker Cancer Centre and University of Calgary, Calgary, Canada.
FAU - Duggan, Peter
AU  - Duggan P
AD  - Tom Baker Cancer Centre and University of Calgary, Calgary, Canada.
FAU - Shafey, Mona
AU  - Shafey M
AD  - Tom Baker Cancer Centre and University of Calgary, Calgary, Canada.
FAU - Stewart, Douglas
AU  - Stewart D
AD  - Tom Baker Cancer Centre and University of Calgary, Calgary, Canada.
LA  - eng
PT  - Journal Article
DEP - 20230911
PL  - United States
TA  - Transplant Cell Ther
JT  - Transplantation and cellular therapy
JID - 101774629
SB  - IM
MH  - Humans
MH  - Adolescent
MH  - Young Adult
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Retrospective Studies
MH  - Transplantation, Autologous
MH  - Disease-Free Survival
MH  - *Lymphoma, Large B-Cell, Diffuse/diagnostic imaging/therapy
MH  - Alberta
OTO - NOTNLM
OT  - Autologous stem cell transplantation
OT  - Large B cell lymphoma
OT  - Real-world evidence
EDAT- 2023/09/14 00:42
MHDA- 2023/12/04 12:42
CRDT- 2023/09/13 19:13
PHST- 2023/08/12 00:00 [received]
PHST- 2023/08/30 00:00 [revised]
PHST- 2023/09/07 00:00 [accepted]
PHST- 2023/12/04 12:42 [medline]
PHST- 2023/09/14 00:42 [pubmed]
PHST- 2023/09/13 19:13 [entrez]
AID - S2666-6367(23)01519-1 [pii]
AID - 10.1016/j.jtct.2023.09.005 [doi]
PST - ppublish
SO  - Transplant Cell Ther. 2023 Dec;29(12):763.e1-763.e5. doi: 
      10.1016/j.jtct.2023.09.005. Epub 2023 Sep 11.